Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study

Fatemeh Saberi Hosnijeh*, Lina van der Straten, Arnon P. Kater, Marinus H. J. van Oers, Ward F. M. Posthuma, Martine E. D. Chamuleau, Mar Bellido, Jeanette K. Doorduijn, Michel van Gelder, Mels Hoogendoorn, Fransien de Boer, G. Doreen te Raa, J. Martijn Kerst, Erik W. A. Marijt, Reinier A. P. Raymakers, Harry R. Koene, Martijn R. Schaafsma, Johan A. Dobber, Sanne H. Tonino, Sabina S. KerstingAnton W. Langerak, Mark-David Levin

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)55-60.e6
Number of pages12
JournalExperimental Hematology
Volume89
DOIs
Publication statusPublished - Sep 2020

Keywords

  • SOLUBLE CD23
  • MATRIPTASE
  • EXPRESSION
  • STAGE
  • RISK

Cite this